Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil.
Acurcio, Francisco A; Machado, Marina A A; Moura, Cristiano S; Ferre, Felipe; Guerra, Augusto A; Andrade, Eli I G; Cherchiglia, Mariangela L; Rahme, Elham.
Arthritis Care Res (Hoboken)
; 68(10): 1489-96, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-26814681
Biologic interventions for fatigue in rheumatoid arthritis.
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
[Pregnant patient with rheumatoid arthritis treated with methotrexate and infliximab].
[Association of short-term efficacy for infliximab in rheumatoid arthritis with plasma concentration and anti-drug antibody].
Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis.
Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis.
IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis.
Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan.